333 related articles for article (PubMed ID: 15747240)
41. Immunological responses to pneumococcal vaccine in frail older people.
Ridda I; Macintyre CR; Lindley R; Gao Z; Sullivan JS; Yuan FF; McIntyre PB
Vaccine; 2009 Mar; 27(10):1628-36. PubMed ID: 19100304
[TBL] [Abstract][Full Text] [Related]
42. ["Herd immunity" after administration of Pneumococcal conjugate vaccine and its impact on vaccination campaigns].
Ciriminna S; Cuccia M
Ann Ig; 2002; 14(6 Suppl 7):39-42. PubMed ID: 12638363
[TBL] [Abstract][Full Text] [Related]
43. Emergence of Streptococcus pneumoniae serotypes 19A, 6C, and 22F and serogroup 15 in Cleveland, Ohio, in relation to introduction of the protein-conjugated pneumococcal vaccine.
Jacobs MR; Good CE; Bajaksouzian S; Windau AR
Clin Infect Dis; 2008 Dec; 47(11):1388-95. PubMed ID: 18959493
[TBL] [Abstract][Full Text] [Related]
44. Immunogenicity of a combined schedule of 7-valent pneumococcal conjugate vaccine followed by a 23-valent polysaccharide vaccine in adult recipients of heart or lung transplants.
Gattringer R; Winkler H; Roedler S; Jaksch P; Herkner H; Burgmann H
Transpl Infect Dis; 2011 Oct; 13(5):540-4. PubMed ID: 21489090
[TBL] [Abstract][Full Text] [Related]
45. Empiric first-line antibiotic treatment of acute otitis in the era of the heptavalent pneumococcal conjugate vaccine.
Garbutt J; Rosenbloom I; Wu J; Storch GA
Pediatrics; 2006 Jun; 117(6):e1087-94. PubMed ID: 16740811
[TBL] [Abstract][Full Text] [Related]
46. Immunogenic protein contaminants in pneumococcal vaccines.
Yu J; Briles DE; Englund JA; Hollingshead SK; Glezen WP; Nahm MH
J Infect Dis; 2003 Mar; 187(6):1019-23. PubMed ID: 12660950
[TBL] [Abstract][Full Text] [Related]
47. Immunogenicity of pneumococcal vaccine in heart transplant recipients.
Blumberg EA; Brozena SC; Stutman P; Wood D; Phan HM; Musher DM
Clin Infect Dis; 2001 Jan; 32(2):307-10. PubMed ID: 11170924
[TBL] [Abstract][Full Text] [Related]
48. [Serotype 19F pneumococcal meningitis in an imunocompetent infant immunized with heptavalent pneumococcal conjugated vaccine Prevenar].
Isapof A; Delacourt C; Reinert P; Cohen R; Madhi F
Arch Pediatr; 2009 Aug; 16(8):1133-6. PubMed ID: 19500954
[TBL] [Abstract][Full Text] [Related]
49. Prophylaxis against postsplenectomy pneumococcal infection.
Siddins M; Downie J; Wise K; O'Reilly M
Aust N Z J Surg; 1990 Mar; 60(3):183-7. PubMed ID: 2183753
[TBL] [Abstract][Full Text] [Related]
50. Immunogenicity for 16 serotypes of a unique schedule of pneumococcal vaccines in a high-risk population.
Leach AJ; Morris PS; Mackenzie G; McDonnell J; Balloch A; Carapetis J; Tang M
Vaccine; 2008 Jul; 26(31):3885-91. PubMed ID: 18562052
[TBL] [Abstract][Full Text] [Related]
51. Heptavalent pneumococcal conjugate vaccine: current and future impact.
Hsu KK; Pelton SI
Expert Rev Vaccines; 2003 Oct; 2(5):619-31. PubMed ID: 14711324
[TBL] [Abstract][Full Text] [Related]
52. Validation of current joint American Academy of Allergy, Asthma & Immunology and American College of Allergy, Asthma and Immunology guidelines for antibody response to the 23-valent pneumococcal vaccine using a population of HIV-infected children.
Kamchaisatian W; Wanwatsuntikul W; Sleasman JW; Tangsinmankong N
J Allergy Clin Immunol; 2006 Dec; 118(6):1336-41. PubMed ID: 17157665
[TBL] [Abstract][Full Text] [Related]
53. Does the 23-valent pneumococcal vaccine protect cochlear implant recipients?
Hey C; Rose MA; Kujumdshiev S; Gstoettner W; Schubert R; Zielen S
Laryngoscope; 2005 Sep; 115(9):1586-90. PubMed ID: 16148699
[TBL] [Abstract][Full Text] [Related]
54. Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005.
Messina AF; Katz-Gaynor K; Barton T; Ahmad N; Ghaffar F; Rasko D; McCracken GH
Pediatr Infect Dis J; 2007 Jun; 26(6):461-7. PubMed ID: 17529859
[TBL] [Abstract][Full Text] [Related]
55. Poor antibody response to pneumococcal polysaccharide vaccination suggests increased susceptibility to pneumococcal infection in splenectomized patients with hematological diseases.
Cherif H; Landgren O; Konradsen HB; Kalin M; Björkholm M
Vaccine; 2006 Jan; 24(1):75-81. PubMed ID: 16107293
[TBL] [Abstract][Full Text] [Related]
56. Effect of pneumococcal vaccination: a comparison of vaccination rates in patients with bacteremic and nonbacteremic pneumococcal pneumonia.
Musher DM; Rueda-Jaimes AM; Graviss EA; Rodriguez-Barradas MC
Clin Infect Dis; 2006 Oct; 43(8):1004-8. PubMed ID: 16983612
[TBL] [Abstract][Full Text] [Related]
57. Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine.
Albrich WC; Baughman W; Schmotzer B; Farley MM
Clin Infect Dis; 2007 Jun; 44(12):1569-76. PubMed ID: 17516400
[TBL] [Abstract][Full Text] [Related]
58. [Two pneumococcal vaccines: the 7-valent conjugate vaccine (Prevenar) for children up to the age of 5 years and the 23-valent polysaccharide vaccine (Pneumo 23) for the elderly and specific groups at risk].
de Greeff SC; Sanders EA; de Melker HE; van der Ende A; Vermeer PE; Schouls LM
Ned Tijdschr Geneeskd; 2007 Jun; 151(26):1454-7. PubMed ID: 17633974
[TBL] [Abstract][Full Text] [Related]
59. [Missing spleen: indication for pneumococcal vaccination].
van Dijk GW; van Leeuwen HJ; van Gijn J; Hoepelman IM
Ned Tijdschr Geneeskd; 2003 Mar; 147(10):425-8. PubMed ID: 12666509
[TBL] [Abstract][Full Text] [Related]
60. Can the response to 23-valent pneumococcal vaccine in splenectomised patients be predicted?
Llupià A; Vilella A; Costas L; Díez C; Torres F; Yagüe J; Massó M; Muñoz A; Mensa J
Vaccine; 2012 Mar; 30(13):2382-6. PubMed ID: 21964060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
